glp-1 psychiatric side effects Exploring the of Receptor Agonist: To Ensure Its Optimal Positioning Psychotropic effects of GLP-1R agonists

What sets Retatrutide apart is its innovative mechanism: it is a triple agonist peptide, meaning it simultaneously activates three crucial receptors involved in metabolic regulation: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors

Around 40-50% of GLP-1 users report nausea or bloating in the early stages of treatment, though symptoms should settle in the first 4-8 weeks as the body adapts (2)

Mounjaro works by helping the body release insulin when blood sugar is high, remove excess sugar from the blood, stop the liver from making and releasing too much sugar, reduce how much food is eaten and slow down how quickly food leaves the stomach

AOM trial: Patients with obesity but without T2D, comparing newer GLP-1 RAs to older GLP-1 RAs and other anti-obesity medications (AOMs)